Latest Recruitment News

Imagion Biosystems has raised $3.75 million to fund the start of its Phase 1b/2 clinical trial for the MagSense HER2 imaging agent in the US, following FDA clearance. The capital raising involves a two-tranche share placement with free attaching options, led by CPS Capital.

LTR Pharma’s intranasal spray OROFLOW® has secured ethics approval for a clinical study targeting oesophageal motility disorders, marking its first foray beyond erectile dysfunction. The study, led by Dr Peter Wu, aims to validate a non-invasive alternative for swallowing difficulties in a market projected to reach US$8.1 billion by 2034.

WasteCo Group’s Chair Roger Gower will resign in July 2026, with Sean Joyce stepping up as Chair amid ongoing CEO recruitment and operational upgrades.

Recce Pharmaceuticals has secured ethics approval to upgrade and broaden its pivotal Phase 3 trial of RECCE® 327 Topical Gel for diabetic foot infections in Australia, accelerating recruitment and reinforcing its global registration ambitions.

Emyria has trained its first cohort of 31 clinicians in New South Wales, paving the way for its inaugural Sydney Empax clinic at Matilda Nepean, scheduled to open in Q3 2026.

Altair Minerals has strengthened its exploration leadership by appointing Dr. Sonia Scarselli as Specialist Advisor and forming a joint Technical Committee with Endeavour Mining to accelerate its Greater Oko Project in Guyana.

Actinogen Medical’s pivotal XanaMIA Alzheimer’s trial has passed a third independent safety review, endorsing continuation without changes. Final topline efficacy data is expected in November 2026.

Regener8 Resources is transitioning its leadership as founder Stephen Foley steps down, paving the way for a new Managing Director with regional operational expertise to steer the company’s next exploration phase in Bosnia and Herzegovina.

Flight Centre Travel Group has trimmed its FY26 profit forecast due to Middle East conflict impacts on leisure travel, while launching a fresh $200 million share buy-back reflecting confidence in recovery.

Sierra Nevada Gold (ASX: SNX) reports 60% completion of its Phase 1 drilling at the As Safra copper-gold project in Saudi Arabia, with promising geological signs and ongoing government backing.

EDU Holdings lifted total student enrolments by 32% in Trimester 2 2026, driven by strong growth at its higher education arm Ikon Institute, offsetting softness in its vocational training division.

Neurizon Therapeutics has dosed over 50% of participants in the HEALEY ALS Platform Trial's Regimen I, exceeding recruitment expectations after expanding the cohort from 160 to 240 patients. The accelerated pace puts the company on track for last patient dosing in Q2 2027 and topline results by early Q3 2027.